-
myMDAnderson
Log in to our secure, personalized website to manage your care.
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
MENU
Leukemia Clinical Trials
Phase I Agents for Hematologic Malignancies
- Dasatinib + DAC (2011-0333)
- Ruxolitinib (2012-0697)
- AC220 + LD Ara-C (2012-1047)
- GSK525762 (2013-0527)
- MEDI4736 (2013-1041)
- FF-10501-01 (2014-0014)
- ASTX727 (2014-0089)
- Ruxolitinib + DAC (2014-0344)
- OPN-305 (2014-0432)
- Bosutinib + Inotuzumab (2014-0435)
- ABT-199 +/- AZA (2014-0490)
- DS-3032B (2014-0565)
- ONC201 (2014-0731)
- BGB324 (2014-0756)
- AG-120 (2014-0800)
- SL-401(2014-0860)
- SL-401(2014-0976)
- Oral ABL001 (2014-1019)
- LY3039478 + Dexamethasone (2015-0020)
- AMG 330 (2015-0296)
- LY2510924 + Ida + Ara-C (2015-0436)
- ADCT-402 (2015-0618)
- LY2606368 + Ara-C + Fludarabine (2015-0665)
- AG-120 or AG-221 + 7+3 (2015-0767)
- BLU-285 (2015-0832)
- Venetoclax + Cobimetinib or Venetoclax + Idasanutlin (2015-0898)
- ADCT-402 (2015-0985)
- IMGN779 (2015-1024)
- AG-120 or AG-221 + AZA (2015-1056)
- AGS67E (2015-1129)
- FT-2102 (2016-0150)
- XmAb 14045 (2016-0165)
- ORH-2014 (2016-0291)
- SEL24 (2016-0713)
- H3B-8800 (2016-0547)
- SGN-CD123 (2016-0454)
- GSK2879552 (2016-0401)
- AGS62P1 (2016-0647)
- K0706 (2016-0648)
- UCART123 in BPDCN (2016-0840)
- DS-3201b (2016-1130)
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Hyper-CVAD + Ofatumumab (2010-0708)
- Hyper-CVAD + Blinatumomab (2014-0845)
- Hyper-CMAD + Vincristine (2008-0598)
- mHCVD + Inotuzumab +/-Blinatumomab (2010-0991)
- Hyper-CVAD + Ponatinib (2011-0030)
- Bosutinib + Inotuzumab (2014-0435)
- EPOCH + Ofatumumab or Rituximab (2014-0123)
Minimal Residual Disease
- Blinatumomab (2014-0844)
Salvage Programs
- KTE-C19 (2015-0416)
- ADCT-402 (2015-0985)
- Ruxolitinib or Dasatinib + HyperCVAD (2014-0521)
- ADCT-301 (2015-0618)
- EPOCH + Ofatumumab (2014-0123)
- Bosutinib + Inotuzumab (2014-0435)
- Oral ABL001 (2014-1019)
- LY3039478 + Dexamethasone (2015-0020)
Phase I/II Open to ALL
- mHCVD + Inotuzumab +/- Blinatumomab (2010-0991)
- KTE-C19 (2015-0416)
- ADCT-402 (2015-0985)
- DS-3201B (2016-1130)
- ONC201 (2014-0731)
Acute Myelogenous Leukemia (AML)
Newly Diagnosed
- Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147)
- ATRA and arsenic +/- Gemtuzumab (2010-0981)
- Nivolumab + Ida + Ara-C (2014-0907)
- Cladribine + Ida + Ara-C (2012-0648)
- CPX-351 (2014-0548)
- BP1001 + LD Ara-C (2016-0128)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
- ABT-199 + AZA (2014-0490)
- Nivolumab + AZA (2014-0861)
- DAC (2012-1017)
- DAC + JNJ-56022473 vs DAC (2015-0526)
- Inecalcitol + DAC (2016-0198)
- AZA + Durvalumab (2016-0182)
- AG-120 or AG-221 + AZA (2015-1056)
- SEL24 (2016-0713)
- SGI-110 (2013-0843)
FLT3 Mutated Only
- ASP2215 vs ASP2215 + AZA vs AZA (2016-0266)
- AC220 + AZA or LD Ara-C (2012-1047)
- Sorafenib + AZA (2014-0076)
IDH Mutated only
- AG-221 vs conventional care (2015-0781)
- FT-2102 (2016-0150)
- AG-120 or AG-221 +7 + 3 (2015-0767)
- BAY 1436032 (2016-1084)
- ABT-199 +/- AZA (2014-0490)
- AG-120 (2014-0800)
- AG-120 or AG-221 + AZA (2015-1056)
Frontline AML Post-Hypomethylating Therapy for MDS
- Nivolumab + AZA (2014-0861)
Secondary Leukemia
Mixed Phenotype Acute Leukemia
- Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073)
Salvage
FLT3 Positive at relapse
- ASP2215 vs Salvage Chemo (2015-0604)
- AlloSCT Initial Salvage Therapy (2014-0358)
- AC220 + LD Ara-C (2012-1047)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- SY-1425 (2016-0460)
- AMG 330 (2015-0296)
- XmAb 14045 (2016-0165)
- SEL24 (2016-0713)
- Selinexor + Sorafenib (2014-0975)
RAS Mutated
AML with MLL gene at 11q23 Translocations
- SY-1425 (2016-0460)
IDH Mutated
- AG-221 vs conventional (2015-0781)
- AlloSCT Initial Salvage Therapy (2014-0358)
- FT-2102 (2016-0150)
- AG-120 (2014-0800)
- SY-1425 (2016-0460)
- AMG 330 (2015-0296)
- XmAb 14045 (2016-0165)
All others (Regardless of mutation status)
- Alvocidib (Flavopiridol)/Ara-C/Mitoxantrone (FLAM) (2015-0719)
- AlloSCT Initial Salvage Therapy (2014-0358)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- SY-1425 (2016-0460)
- Nivolumab + AZA (2014-0861)
- Lirilumab + AZA (2014-0862)
- LY2606368 + Ara-C + Flu (2015-0665)
- DS-3032B (2014-0565)
- AMG 330 (2015-0296)
- Nivolumab + AZA (2014-0861)
- XmAb 14045 (2016-0165)
- ADCT-301 (2015-0618)
- Avelumab (2016-0444)
- SEL24 (2016-0713)
- SGN-CD123 (2016-0454)
- IACS-010759 (2016-0250)
- DS-3032B (2014-0565)
- SGI-110 (2016-0828)
Maintenance (Patients in CR)
Myelodysplastic Syndrome (MDS) (Includes CMML)
Specific Situations
Hypoplastic MDS and aplastic anemia
Splicing Mutations
- H3B-8800 (2016-0547)
MDS/MPN
FLT3 Positive
RAS Mutated
- MEK162 (2013-0116)
IDH 1/2 Mutations
Low Risk/IPSS Int-1
- Talacotuzumab (2016-0969)
- Oral AZA + BSC vs Placebo + BSC (2012-0733)
- Nivolumab + Ipilimumab + Aza (2014-0930)
- Lirilumab + Aza (2014-0934)
- DAC vs AZA (2014-0112)
IPSS int-2 or high
- Nivolumab + Ipilimumab + Aza (2014-0930)
- Lirilumab + Aza (2014-0934)
- SGI-110 (2013-0901)
- AZA + Durvalumab (2016-0182)
- Oral Rigosertib + AZA (2013-0030)
- Ruxolitinib + AZA (2012-0737)
- SL-401 (CMML) (2014-0976)
- Cladribine + LD Ara-C alt DAC (2011-0987)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
MDS ≥ 20% Blasts
- SGI-110 (2013-0843)
- DAC (2012-1017)
- Ruxolitinib + DAC (2014-0344)
- Nivolumab + Ida + Ara-C (2014-0907)
Post Hypomethylating Agents
- Talacotuzumab (2016-0969)
- Nivolumab + Ipilimumab + Aza (2014-0930)
- OPN-305 (2014-0432)
- SGI-110 (2016-0587)
- CC-486 (2015-0056)
- SL-401 (CMML) (2014-0976)
- Omacetaxine (2013-0870)
- Nivolumab + AZA (2014-0861)
- Rigosertib (2015-0360)
- Oral Rigosertib + AZA (2013-0030)
- FF-10501-01 (2014-0014)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- SL-401 (CMML) (2014-0976)
- MEDI4736 (2013-1041)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
- Ruxolitinib (2015-0570)
Untreated - all stages
- FCIG (2015-0281)
- Venetoclax + Ibrutinib (2015-0860)
- Ibrutinib + Venetoclax (2016-0875)
- CC-122 (2015-0193)
- Atezolizumab (2015-1097)
- Ublituximab + TGR-1202 Vs Obinutuzumab + Chlorambucil (2016-0116)
- Lirilumab + Rituximab (2014-0933)
Consolidation and Minimal Residual Disease (MRD)
Prior Therapy
- Venetoclax + Ibrutinib (2015-0860)
- Lenalidomide + Obinutuzumab (2014-0115)
- CC-122 (2015-0193)
- Atezolizumab (2015-1097)
- Durvalumab (2015-1108)
- BGB-3111 (2016-0396)
- XmAb®13676 (2016-0991)
- ACP-196 vs Ibrutinib (2015-0821)
- Nivolumab + Ibrutinib (2014-0931)
- Lirilumab + Rituximab (2014-0933)
- IPI-145 Extension Study (2016-0120)
Richter’s Transformation
Other Studies
Chronic Myelogenous Leukemia (CML)
Chronic phase
- Dasatinib (2015-1040)
- Bosutinib (2016-0081)
- K0706 (2016-0648)
- Oral ABL001 (2014-1019)
- Ponatinib (2015-0212)
- Axitinib + Bosutinib (2015-0787)
Accelerated Phase
- K0706 (2016-0648)
- Dasatinib + DAC (2011-0333)
- Axitinib + Bosutinib (2015-0787)
- Oral ABL001 (2014-1019)
Blastic Phase
- Dasatinib + DAC (2011-0333)
- Axitinib + Bosutinib (2015-0787)
- Bosutinib + Inotuzumab (2014-0435)
- K0706 (2016-0648)
- DS-3032B (2014-0565)
Imatinib failures with T315l mutations (any stage)
Minimal Residual Disease
- Ruxolitinib (2012-0697)
Myeloproliferative Diseases
- Nivolumab (2014-0962)
- INCB050465 + Ruxolitinib (2016-0233)
- Sotatercept (ACE-011) (2012-0534)
- LCL-161 (2013-0612)
- SL-401 (2014-0976)
- Ruxolitinib + AZA (2012-0737)
- BLU-285 (2015-0832)
- INCB054828 (2016-0635)
- SL-401 (2014-0976)
- Ruxolitinib in Mutation of CSF3R (2014-0764)
- INCB054828 (2016-0635)
Hemophagocytic Lymphohistiocytosis
- Alemtuzumab + Etoposide & Dexamethasone (2014-0989)